Tuesday, March 04, 2014
SERUM / BBIO -
Inactivated Polio Vaccine (IPV) made available at affordable prices to the
Pune, India: Serum
Institute of India and
Bilthoven Biologicals B.V, The Netherlands, have endeavoured to
support the Programme to reach the Global Polio Eradication Initiative [GPEI]
Endgame Strategic Plan 2013-2018, by substantially reducing the price of
IPV from the prevailing price available in the market, in the recent
tender bid with UNICEF.
This is for the first time that the two Companies have joined hands
together to make IPV available to UNICEF at a subsidized rate, which
resulted in triggering a global reduction in price of IPV .
Dr. Roeland van Dam, CEO of Bilthoven Biologicals announced the reduction
in IPV price for the first time compared to the prevailing price of IPV,
solely due to the financial subsidization of the cost provided by Serum
Institute of India. This has been achieved with the objective of providing
vaccines to the poorer countries of the world.
Dr. Cyrus S. Poonawalla, Chairman of Serum Institute of India, stated that
he was proud to support the IPV programme to reach the GPEI Endgame
Strategic Plan 2013-2018, in keeping with his commitment to the World
Health Organization to make available Polio vaccine as affordable as
possible. With the R&D efforts that are put in, he is confident that the
price of IPV will further reduce in the future.
Both Bilthoven Biologicals and Serum Institute of India continue their
efforts to develop their production both in numbers and reduction in price
for the future, which benefit they expect to pass on [as they have done
several times in the past] to the poorer countries requiring vaccine for
moving towards the GPEI Endgame Strategic Plan 2013-2018.
Recently Serum Institute of India has stepped-in to resolve the acute
shortage of hundreds of million doses of OPV (Oral Polio Vaccine),
required by the U.N. Agencies, at short notice and at affordable prices,
thus mitigating a Polio vaccine availability crisis.
It would be relevant to note that Bilthoven Biologicals has not only
offered a special price for the poorer countries compared to their past
price, but extended this uniformly to all other 120 countries which were
equally in need of this vaccine to be introduced for achieving the GPEI
Endgame Strategic Plan 2013-2018